Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03384784 · ClinicalTrials.gov registry record · Phase 2
Effect of Galantamine on Inflammation and Cognition
A Phase 2 study of HIV Associated Cognitive Motor Complex, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT03384784: Completed Phase 2 study of HIV Associated Cognitive Motor Complex, sponsored by University of Pennsylvania.
NCT03384784 is a Phase 2 study of HIV Associated Cognitive Motor Complex that has completed, run by University of Pennsylvania. The registered enrollment target is 63 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03384784, a Phase 2 study of HIV Associated Cognitive Motor Complex, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
This study tests whether galantamine (GAL) reduces HIV-related inflammation and cognitive deficits. In this double-blind placebo-controlled crossover study, HIV-infected individuals (N=120; 60 smokers and 60 non-smokers) will be randomized to 12 weeks of GAL or placebo, followed by a 4-week washout, then 12 weeks of GAL or placebo (arms switched). Outcomes are monocyte/macrophage and T cell activation and neurocognitive performance.
Primary Outcome
Cognitive function will be assessed 4 times at Lab Visits. Executive function was measured by the task switch cost from the Color shape task, measured in ms. Executive function was also measured via response time (ms) and accuracy (# correct) on an N-back working memory task. Verbal learning and memory were measured by the Total Recall and Delayed Recall, respectively, from the Hopkins Verbal Learning Test. Response inhibition was measured by the stop signal reaction time (ms) from the Stop Sign
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Galantamine
Study Locations (1)
Pennsylvania
- Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2017-10-30 |
| Est. Completion | 2022-05-31 |
| Phase | Phase 2 |
What the finished NCT03384784 record still lists
NCT03384784 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (53% lower).
The record links to 1 condition, with HIV Associated Cognitive Motor Complex appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03384784 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03384784 about?
NCT03384784 is a clinical study titled "Effect of Galantamine on Inflammation and Cognition". This study tests whether galantamine (GAL) reduces HIV-related inflammation and cognitive deficits. In this double-blind placebo-controlled crossover study, HIV-infected individuals (N=120; 60 smokers and 60 non-smokers) will be randomized to 12 weeks of GAL or placebo, followed by a 4-week washout,...
What is the current status of trial NCT03384784?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2017-10-30. Estimated completion is 2022-05-31.
What conditions does trial NCT03384784 study?
This clinical trial studies the following conditions: HIV Associated Cognitive Motor Complex.
What interventions are being tested in trial NCT03384784?
The interventions under investigation include: Placebo (DRUG), Galantamine (DRUG).
Who is sponsoring clinical trial NCT03384784?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03384784 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Associated Cognitive Motor Complex
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03384784's enrollment target sits among peer trials
63 1009th of 2000 higher than 985 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI